Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
8(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
8%
Ph not_applicable
1
8%
Ph phase_1
2
17%
Ph phase_2
3
25%
Ph phase_3
3
25%

Phase Distribution

3

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

12

all time

Status Distribution
Active(10)
Completed(2)

Detailed Status

Active, not recruiting6
Recruiting2
Completed2
Enrolling by invitation1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 12 (20.0%)
Phase 23 (30.0%)
Phase 33 (30.0%)
N/A1 (10.0%)

Trials by Status

active_not_recruiting650%
enrolling_by_invitation18%
not_yet_recruiting18%
recruiting217%
completed217%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT07544953Not Applicable

Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

Not Yet Recruiting
NCT05925621

Cognitive Neurology Unit Clinical Registry

Recruiting
NCT04468659Phase 3

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Active Not Recruiting
NCT06384573Phase 3

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Active Not Recruiting
NCT05269394Phase 2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Active Not Recruiting
NCT01760005Phase 2

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active Not Recruiting
NCT06602258Phase 2

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Active Not Recruiting
NCT06285448

Feasibility of Lecanemab Registry and Clinical Outcome Measures

Enrolling By Invitation
NCT05469009Early Phase 1

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Active Not Recruiting
NCT06530732Phase 3

Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)

Recruiting
NCT05533801Phase 1

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Completed
NCT05045716Phase 1

A Study of Subcutaneous Lecanemab in Healthy Participants

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12